Friday broker round-up UPDATE
13th Dec 2013 09:36
African Barrick Gold: JP Morgan lowers target price from 180p to 170p leaving its neutral rating unaltered. Aggreko: Numis reduces target price from 1400p to 1234p downgrading from reduce to sell. Anglo American: Deutsche Bank reduces target price from 1780p to 1500p and downgrades to hold. JP Mor
Read moreAstrazeneca's diabetes drug wins approval from FDA advisory committee
13th Dec 2013 07:39
Drug maker AstraZeneca, in partnership with Bristol-Myers Squibb, on Friday revealed that the US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) gave its approval of their diabetes treatment, dapagliflozin. The FDA takes the EMDAC's advice into ac
Read moreLondon pre-open: FTSE to nudge higher ahead of quiet session
13th Dec 2013 07:26
City sources predict the FTSE 100 will open three points higher than yesterday's close of 6,445.25, ticking marginally higher after a week of declines. It looks set to be a quiet session on both the company and macro fronts, as investors digest the news out from the US last night that the House in
Read moreFTSE 100 movers: Sports Direct dives in spite of leap in H1 profit
12th Dec 2013 15:17
Sportswear and equipment retailer Sports Direct slumped today despite delivering a near-17 per cent jump in underlying profits during its first half, driven by an increase in online and international sales. However, the company did say that '[current] trading has now reverted to management's origina
Read moreAstraZeneca diabetes drug requires more testing
12th Dec 2013 07:12
- Panel recommends for narrow application - More evidence called before wider recommendation Advisers to the US drugs regulator refused to back a wider application of AstraZeneca and Bristol-Myers Squibb's medicine metreleptin, but did recommend it for a narrower range of people. The US Food and
Read moreLondon close: Stocks surge as strong US data offsets taper fears
6th Dec 2013 16:55
- FTSE 100 rebounds strongly on US jobs beat - Taper expectations brought forward - Oil, housing stocks provide a lift techMARK 2,670.64 +0.85% FTSE 100 6,551.99 +0.83% FTSE 250 15,317.05 +1.05% After falling to an eight-week low the previous session, the FTSE 100 rallied on Friday after a much be
Read moreLondon midday: Markets bounce back ahead of US data
6th Dec 2013 11:31
- FTSE 100 rebounds from worst level in eight weeks - Oil, housing stocks provide a lift - Markets focus on non-farm payrolls ahead of Fed meeting techMARK 2,657.20 +0.34% FTSE 100 6,536.26 +0.58% FTSE 250 15,210.58 +0.35% Strong gains in oil and housing sectors were providing a lift in London on
Read moreLondon open: Housing, oil stocks help markets rebound from eight-week low
6th Dec 2013 08:52
- Housing and oil stocks provide a lift - Focus on Fed ahead of non-farm payrolls - Berkeley jumps as strong housing demand boosts H1 results techMARK 2,650.07 +0.07% FTSE 100 6,518.46 +0.31% FTSE 250 15,166.21 +0.06% The FTSE 100 rebounded slightly on Friday from an eight-week low, as bargain hu
Read moreLondon pre-open: Small rebound expected ahead of US jobs report
6th Dec 2013 07:37
Markets are expected to open slightly higher on Friday morning, rebounding after recent losses which have sent the FTSE 100 to an eight-week low, as investors look ahead to some key economic data out from the States this afternoon. City sources predict the FTSE 100 will open up around 13 points low
Read moreAstraZeneca receives European approval for child flu vaccine
6th Dec 2013 07:18
Pharmaceutical giant AstraZeneca has announced that the European Commission (EC) has granted marketing authorisation to its nasally administered four-strain flu vaccine Fluenz Tetra. The vaccine, aimed for the prevention of influenza in children and adolescents from 24 months to 18 years of age, i
Read moreLondon close: FTSE closes slightly lower after data-heavy week
22nd Nov 2013 16:48
- FTSE down seven points, 19 on the week - German GDP in-line - Former Co-op Bank Chairman arrested - TUI sinks on share sale - AstraZeneca rises on recommendation from EMA techMARK 2,642.04 +0.25% FTSE 100 6,674.30 -0.11% FTSE 250 15,187.68 +0.26% The final session of the week saw the FTSE end se
Read moreAstrazeneca rises on progress with diabetes drug
22nd Nov 2013 15:28
Shares in biopharmaceutical business AstraZeneca received a boost on Friday afternoon after the company, alongside sector peer Bristol-Myers Squibb, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended approval of Xigduo, a t
Read moreFTSE 100 movers: AstraZeneca rises on drug recommendation, TUI sinks
22nd Nov 2013 15:19
Shares in biopharmaceutical business AstraZeneca received a boost on Friday afternoon after the company, alongside sector peer Bristol-Myers Squibb, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had recommended approval of Xigduo, a t
Read moreFTSE 100 movers: Johnson Matthey tops leaders after results impress
21st Nov 2013 15:07
Shares in speciality chemicals company Johnson Matthey leapt to the top of the leaderboard after it reported a robust set of half-year results, powered by a strong performance in Emission Control Technologies ahead of new European legislation and good demand for Process Technologies' products. The
Read moreWednesday broker round-up UPDATE
20th Nov 2013 08:46
Afren: Liberum Capital raises target price from 197p to 232p and maintains a buy recommendation. AstraZeneca: Berenberg cuts target price from 3472p to 3430p reiterating a hold recommendation. AVEVA Group: Liberum Capital reduces target price from 2350p to 2250p and keeps its hold recommendation.
Read more